Wire · opportunities
Boehringer, Envisagenics sign $1B multi-target oncology collaboration
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 September 2026 · Fusion42 review
Boehringer Ingelheim and AI drug discovery company Envisagenics have entered a potential $1 billion multi-year collaboration to validate tumor-specific oncology targets using Envisagenics' AI platform SpliceCore, focusing on RNA splicing. This agreement supports Envisagenics' internal CNS candidate and offers Boehringer exclusive licensing options for antibody-drug conjugates, T-cell engagers, and multi-specific antibodies.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
AI drug discovery just secured a $1 billion validation and development boost in oncology, opening a door for biotech founders working on RNA splicing targets to partner with major pharmaceutical companies like Boehringer. You can expect faster clinical progression and new licensing opportunities from tumour-specific therapeutics as big pharma bets on AI platforms.
◆ Coverage
1 source · 22 Sep 2026
◆ Related on Wire
◆ Topics